Cabazitaxel CAS 183133-96-2 for Anti-Cancer
Product Description
| CAS No. | 183133-96-2 |
| Appearance | White Powder |
| Molecular Formula | C45H57NO14 |
| Molecular Weight | 835.93 |
| EINECS No. | 680-632-7 |
| Melting Point | 180 °C |
| Boiling Point | 870.7±65.0 °C(Predicted) |
| Density | 1.31 |
| Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
| Shelf Life | 2 Years |
| MOQ | 10 Gram |
Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Function and Application
Cabazitaxel's anti-cancer mechanism and characteristics are similar to docetaxel and belong to anti-microtubule drugs. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.
